Nevolat (Liraglutide)

Liraglutide, the active ingredient in Nevolat, is a glucagon‑like peptide‑1 (GLP‑1) receptor agonist presented as a sterile solution for subcutaneous injection. It is indicated for the management of type 2 diabetes mellitus and for chronic weight management in adult patients with obesity.

GNH USA supplies Nevolat as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under appropriate regulatory frameworks. The company adheres to stringent quality standards and offers cold‑chain logistics to maintain product integrity during global shipment.

Nevolat (liraglutide) is a GLP‑1 receptor agonist used in metabolic disease management.

Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels in adult patients. Obesity: promotes sustained weight loss as part of a comprehensive weight‑management program. Cardiovascular risk reduction: lowers the incidence of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Nevolat may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Constipation - Headache - Decreased appetite

Serious or Rare Side Effects: - Acute pancreatitis - Gallbladder disease (cholelithiasis, cholecystitis) - Severe hypoglycemia (especially with insulin or sulfonylureas) - Anaphylactic reactions - Potential risk of thyroid C‑cell tumors (observed in rodent studies)

Before initiating Nevolat, several safety considerations should be reviewed.

Assess renal function: avoid use in patients with severe renal impairment. Monitor for pancreatitis: discontinue if abdominal pain with elevated enzymes occurs. Evaluate thyroid history: contraindicated in individuals with medullary thyroid carcinoma or MEN 2. Consider hypoglycemia risk: adjust doses of concomitant insulin or sulfonylureas. Pregnancy and lactation: use only if potential benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nevolat can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concurrent insulin or sulfonylureas: increased risk of severe hypoglycemia. - Use with other GLP‑1 receptor agonists: no additive benefit and higher adverse‑event risk. - Combination with medications that markedly delay gastric emptying: may exacerbate gastrointestinal side effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Oral contraceptives: reduced absorption due to delayed gastric emptying. - Beta‑blockers: may mask hypoglycemia symptoms; monitor blood glucose closely.